Evidence map›Paper›PMID 29578938›Full record

ArticleTherapeutic drug monitoring2018

Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application.

Sofia Lindahl, Roar Dyrkorn, Olav Spigset, Solfrid Hegstad

Open access · hybridAbstract read
In one paragraph

Article in Therapeutic drug monitoring, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Sofia LindahlDepartment of Clinical Pharmacology, St. Olav University Hospital, Trondheim, Norway. Dr. Lindahl is now with the Borregaard, Sarpsborg, Norway.
Roar DyrkornDepartment of Clinical Pharmacology, St. Olav University Hospital, Trondheim, Norway. Dr. Lindahl is now with the Borregaard, Sarpsborg, Norway.
Olav SpigsetDepartment of Clinical Pharmacology, St. Olav University Hospital, Trondheim, Norway. Dr. Lindahl is now with the Borregaard, Sarpsborg, Norway.
Solfrid HegstadDepartment of Clinical Pharmacology, St. Olav University Hospital, Trondheim, Norway. Dr. Lindahl is now with the Borregaard, Sarpsborg, Norway.
Borregaard (Norway) · NONorwegian University of Science and Technology · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDirect oral anticoagulants (DOACs) are prescribed for anticoagulation in patients with atrial fibrillation and venous thromboembolic disease. Fixed doses are recommended, but measuring their serum drug concentrations as a basis for dose adjustments may be useful in some clinical settings.

methodsAn ultra-high-performance liquid chromatography-tandem mass spectrometry method for the analysis of the DOACs apixaban, dabigatran, edoxaban, and rivaroxaban in human serum was developed and validated. A 100-µL serum sample was handled using a pipetting robot. Protein precipitation was performed with 375 µL of 1% formic acid in acetonitrile (vol/vol), and phospholipid removal was performed using a Waters Ostro 96-well plate. The injection volume was 1 µL, and run time was 3.0 minutes.

resultsThe calibration range was 5-800 nmol/L. The between-day precision relative SDs were in the range of 3.3%-10%. Recoveries ranged from 85% to 105%, and matrix effects from 88% to 102%, when corrected with internal standard. Edoxaban was, in contrast to the other DOACs, unstable when stored for more than 6 hours at 30°C. The suitability of the method was demonstrated by analyzing routine samples from 345 patients undergoing anticoagulation treatment.

conclusionsThe developed method fulfilled the set validation criteria, and its suitability was demonstrated in a routine setting. The instability of edoxaban may complicate the transport of routine samples to the laboratory.

Indexed as

AntithrombinsChromatography, High Pressure LiquidChromatography, LiquidDabigatranFactor Xa InhibitorsHumansPyrazolesPyridinesPyridonesReproducibility of ResultsRivaroxabanTandem Mass SpectrometryThiazolesAntithrombinsapixabanDabigatranedoxabanFactor Xa InhibitorsPyrazolesPyridinesPyridonesRivaroxabanThiazoles

Identifiers

PMID29578938
PMCPMC5959258
OpenAlexW2793960623

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.